Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Background Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and it often develops in patients with underlying liver cirrhosis. The prevalence of HCC in cirrhotic patients is a significant concern, as it poses a high risk of morbidity and mortality. Aim of this study was Evaluating Hepatocellular carcinoma Prevalence in cirrhotic patients and influencing factors among patients admitted to Urmia Imam Khomeini Hospital ; North-West of Iran from 2016 to 2020. Methods This is a cross-sectional study. Data on hepatocellular carcinoma prevalence and cirrhotic influencing factors were collected from medical records of patients admitted to Imam Khomeini Hospital from 2016 to 2020. Results During the four-year study period, a total of 427 number of patients were admitted to Imam Khomeini Hospital with cirrhotic conditions. Mean (SD) of patients were 59.73(15.3) years. The diagnose rate of HCC was 10.77% (95% CI = 8–14%). HBV and HCV positivity were 26.1% (95% CI = 22–30%) and 6.1% (95% CI = 4–88%) among studied population respectively. HBV and HCV positivity were 63.04% (95% CI = 47–77%) and 10.86% (95% CI = 3.6–26%) among HCC respectively. Rate of reported alcohol consumption was 9.84% (95% CI: 7.18–13.06%). In cirrhotic patients, HBV and Cryptogenic cirrhosis were the most underlying disease among cirrhotic patients (26% and 18.7% of cases, respectively). HBV, Cryptogenic cirrhosis and alcoholic cirrhosis were the most underlying disease among in HCC patients (63% and 4.35% and 4.35% of cases, respectively). Conclusions The research highlights that liver cancer and hepatocellular carcinoma are not the most common cancers in this province, however due to the increasing trend of its predisposing factors and underlying diseases, It is important to have screening programs for people at high risk.
Background Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and it often develops in patients with underlying liver cirrhosis. The prevalence of HCC in cirrhotic patients is a significant concern, as it poses a high risk of morbidity and mortality. Aim of this study was Evaluating Hepatocellular carcinoma Prevalence in cirrhotic patients and influencing factors among patients admitted to Urmia Imam Khomeini Hospital ; North-West of Iran from 2016 to 2020. Methods This is a cross-sectional study. Data on hepatocellular carcinoma prevalence and cirrhotic influencing factors were collected from medical records of patients admitted to Imam Khomeini Hospital from 2016 to 2020. Results During the four-year study period, a total of 427 number of patients were admitted to Imam Khomeini Hospital with cirrhotic conditions. Mean (SD) of patients were 59.73(15.3) years. The diagnose rate of HCC was 10.77% (95% CI = 8–14%). HBV and HCV positivity were 26.1% (95% CI = 22–30%) and 6.1% (95% CI = 4–88%) among studied population respectively. HBV and HCV positivity were 63.04% (95% CI = 47–77%) and 10.86% (95% CI = 3.6–26%) among HCC respectively. Rate of reported alcohol consumption was 9.84% (95% CI: 7.18–13.06%). In cirrhotic patients, HBV and Cryptogenic cirrhosis were the most underlying disease among cirrhotic patients (26% and 18.7% of cases, respectively). HBV, Cryptogenic cirrhosis and alcoholic cirrhosis were the most underlying disease among in HCC patients (63% and 4.35% and 4.35% of cases, respectively). Conclusions The research highlights that liver cancer and hepatocellular carcinoma are not the most common cancers in this province, however due to the increasing trend of its predisposing factors and underlying diseases, It is important to have screening programs for people at high risk.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.